Claims for Patent: 8,986,380

Summary for Patent: 8,986,380

Title:	Multilayered silk scaffolds for meniscus tissue engineering
Abstract:	Provided herein is a biocompatible implant for meniscus tissue engineering. Particularly, the biocompatible implant comprises a multi-layered crescent-shaped silk fibroin scaffold, in which each layer comprises distinct pore size and/or pore orientation, e.g., to mimic native meniscus complex architecture. Accordingly, the biocompatible implant can be used for repairing any meniscal defect or promoting meniscal regeneration in a subject.
Inventor(s):	Kaplan; David L. (Concord, MA), Mandal; Biman B. (Kolkata, IN)
Assignee:	Trustees of Tufts College (Medford, MA)
Application Number:	13/702,606
Patent Claims:	1. A biocompatible implant comprising: a silk fibroin scaffold having at least a first layer and a second layer, wherein the first layer is characterized as having a pore size distribution between about 100 and about 1,000 microns in diameter and comprises two sub-layers, wherein a first sub-layer has a larger pore size distribution than a second sub-layer, and the second layer comprises laminar channels. 2. The biocompatible implant of claim 1, wherein the silk fibroin scaffold further comprises at least one mammalian cell. 3. The biocompatible implant of claim 2, wherein the mammalian cells are human cells. 4. The biocompatible implant of claim 2, wherein the mammalian cells are selected from the group consisting of fibroblasts, chondrocytes, stem cells, bone marrow cells, embryonic stem cells, mesenchymal stem cells, induced pluripotent stem cells, differentiated stem cells, tissue-derived cells, and any combinations thereof. 5. The biocompatible implant of claims 2-4, wherein periphery of the silk fibroin scaffold comprises at least one fibroblast. 6. The biocompatible implant of claim 2, wherein an inner region of the silk fibroin scaffold comprises at least one chondrocyte. 7. The biocompatible implant of claim 2, wherein the silk fibroin scaffold comprise at least one stem cell. 8. The biocompatible implant of claim 1, wherein the first layer comprises approximately circular pores. 9. The biocompatible implant of claim 8, wherein the approximately circular pores are at least partially interconnected. 10. The biocompatible implant of claim 1, wherein the pore size distribution of the first layer ranges from about 200 microns to about 700 microns, or a portion thereof. 11. The biocompatible implant of claim 10, wherein the pore size distribution of the first layer ranges from about 300 microns to about 600 microns, or a portion thereof. 12. The biocompatible implant of claim 1, wherein the first sub-layer is closer to the second layer than the second sub-layer. 13. The biocompatible implant of claim 1, wherein the larger pore size distribution ranges from about 500 microns to about 700 microns. 14. The biocompatible implant of claim 1, wherein the silk fibroin scaffold further comprises a third layer. 15. The biocompatible implant of claim 14, wherein the third layer comprises pores with a pore size distribution ranging from about 10 microns to about 1,000 microns. 16. The biocompatible implant of claim 1, wherein the laminar channels are at least partially aligned. 17. The biocompatible implant of claim 1, wherein the laminar channels have a pore width distribution ranging between about 30 microns and about 100 microns, or a portion thereof. 18. The biocompatible implant of claim 17, wherein the laminar channels have a pore width distribution ranging between about 60 microns and about 80 microns, or a portion thereof. 19. The biocompatible implant of claim 1, wherein the porosity of each layer is independently at least about 30%. 20. The biocompatible implant of claim 1, wherein said each layer is individually formed before stacking together into a single composite unit. 21. The biocompatible implant of claim 1, further comprising at least one extracellular matrix. 22. The biocompatible implant of claim 1, further comprising at least one active agent, wherein the at least one active agent is selected from the group consisting of TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-4, BMP-6, BMP-12, BMP-13, basic fibroblast growth factor, fibroblast growth factor-1, fibroblast growth factor-2, platelet-derived growth factor-AA, platelet-derived growth factor-BB, platelet rich plasma, IGF-I, IGF-II, GDF-5, GDF-6, GDF-8, GDF-10, vascular endothelial cell-derived growth factor, pleiotrophin, endothelin, nicotinamide, glucagon like peptide-I, glucagon like peptide-II, parathyroid hormone, tenascin-C, tropoelastin, thrombin-derived peptides, laminin, biological peptides containing cell-binding domains and biological peptides containing heparin-binding domains, therapeutic agents, and any combinations thereof. 23. The biocompatible implant of claim 1, wherein the silk fibroin scaffold is adapted for meniscus repair or regeneration. 24. The biocompatible implant of claim 23, wherein each layer of the silk fibroin scaffold is crescent-shaped. 25. The biocompatible implant of claim 23, wherein the silk fibroin scaffold is wedge-shaped. 26. The biocompatible implant of claim 1, wherein the thickness of each layer is between about 0.1 mm and 5 mm.

Details for Patent 8,986,380

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2030-06-09